Iovance Biotherapeutics 8K Other Events | IOVA 7 Nov 24

Exhibit 99.1

2 © 2024, Iovance Biotherapeutics, Inc. Forward - Looking Statements Certain matters discussed in this presentation are “forward - looking statements” of Iovance Biotherapeutics, Inc. (hereinafter re ferred to as the “Company,” “we,” “us,” or “our”) within the meaning of the Private Securities Litigation Reform Act of 1995 (the “PSLRA”). Without limiting the foregoing, we may, in some cases, us e terms such as “predicts,” “believes,” “potential,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “forecast,” “guidance,” “outlook,” “may,” “can,” “could,” “might,” “w ill,” “should,” or other words that convey uncertainty of future events or outcomes and are intended to identify forward - looking statements. Forward - looking statements are based on assumptions and assessments made in light of management’s experience and perception of historical trends, current conditions, expected future developments, and other factors believed to be appro pri ate. Forward - looking statements in this presentation are made as of the date of this presentation, and we undertake no duty to update or revise any such statements, whether as a result of new i nfo rmation, future events or otherwise. Forward - looking statements are not guarantees of future performance and are subject to risks, uncertainties, and other factors, many of which are outside of ou r control, that may cause actual results, levels of activity, performance, achievements, and developments to be materially different from those expressed in or implied by these forward - looki ng statements. Important factors that could cause actual results, developments, and business decisions to differ materially from forward - looking statements are described in the sections titled "Risk Factors" in our filings with the U.S. Securities and Exchange Commission, including our most recent Annual Report on Form 10 - K and Quarterly Reports on Form 10 - Q, and include, but a re not limited to, the following substantial known and unknown risks and uncertainties inherent in our business: the risks related to our ability to successfully commercialize our pro ducts, including Amtagvi, for which we have obtained U.S. Food and Drug Administration (“FDA”) approval, and Proleukin, for which we have obtained FDA and European Medicines Agency (“EMA”) app rov al; the risk that the EMA or other ex - U.S. regulatory authorities may not approve or may delay approval for our marketing authorization application submission for lifileucel in me tas tatic melanoma; the acceptance by the market of our products, including Amtagvi and Proleukin, and their potential pricing and/or reimbursement by payors, if approved (in the case of our pro duct candidates), in the U.S. and other international markets and whether such acceptance is sufficient to support continued commercialization or development of our products, including Amtagv i a nd Proleukin, or product candidates, respectively; future competitive or other market factors may adversely affect the commercial potential for Amtagvi or Proleukin; the risk regardin g o ur ability or inability to manufacture our therapies using third party manufacturers or at our own facility, including our ability to increase manufacturing capacity at such third party manufactur ers and our own facility, may adversely affect our commercial launch; the results of clinical trials with collaborators using different manufacturing processes may not be reflected in our sponsor ed trials; the risk regarding the successful integration of the recent Proleukin acquisition; the risk that the successful development or commercialization of our products, including Amtagvi and P rol eukin, may not generate sufficient revenue from product sales, and we may not become profitable in the near term, or at all; the risks related to the timing of and our ability to successfully dev elop, submit, obtain, or maintain FDA, EMA, or other regulatory authority approval of, or other action with respect to, our product candidates; whether clinical trial results from our pivotal studies an d cohorts, and meetings with the FDA, EMA, or other regulatory authorities may support registrational studies and subsequent approvals by the FDA, EMA, or other regulatory authorities, inc lud ing the risk that the planned single arm Phase 2 IOV - LUN - 202 trial may not support registration; preliminary and interim clinical results, which may include efficacy and safety results, from o ngo ing clinical trials or cohorts may not be reflected in the final analyses of our ongoing clinical trials or subgroups within these trials or in other prior trials or cohorts; the risk that enrollment ma y need to be adjusted for our trials and cohorts within those trials based on FDA and other regulatory agency input; the risk that the changing landscape of care for cervical cancer patients may impact o ur clinical trials in this indication; the risk that we may be required to conduct additional clinical trials or modify ongoing or future clinical trials based on feedback from the FDA, EMA, or other reg ulatory authorities; the risk that our interpretation of the results of our clinical trials or communications with the FDA, EMA, or other regulatory authorities may differ from the interpretation of su ch results or communications by such regulatory authorities (including from our prior meetings with the FDA regarding our non - small cell lung cancer clinical trials); the risk that clinical data from ongoing clinical trials of Amtagvi will not continue or be repeated in ongoing or planned clinical trials or may not support regulatory approval or renewal of authorization; the risk that unantici pat ed expenses may decrease our estimated cash balances and forecasts and increase our estimated capital requirements; the risk that we may not be able to recognize revenue for our products; the ris k that Proleukin revenues may not continue to serve as a leading indicator for Amtagvi revenues; the risks regarding our anticipated operating and financial performance, including our financ ial guidance and projections; the effects of global pandemic; the effects of global and domestic geopolitical factors; and other factors, including general economic conditions and regulatory developm ent s, not within our control. Any financial guidance provided in this presentation assumes the following: no material change in our ability to manufacture our products; no material change in payo r c overage; no material change in revenue recognition policies; no new business development transactions not completed as of the period covered by this presentation; and no material fluctuatio n i n exchange rates.

3 © 2024, Iovance Biotherapeutics, Inc. Global Leadership in Innovating, Developing and Delivering TIL Therapy for Patients with Cancer 3 Approved Products Commercial Launch People & Assets 56 >250M >140 ~$ 404M Cash as of 9/30/24 $58.6M 3Q24 Revenue >750 Employees 3 1 1 DESIGNATIONS: Fast Track BTD RMAT Authorized Treatment Centers as of 11/7/24 Amtagvi Patients Treated as of 11/7/24 2 U.S. patient lives covered under payer policies/plans Global Advanced Melanoma Treatment Opportunity >70K Pipeline Clinical Trials 2 10 >700 Ex - U.S. Regulatory Filings Submitted 1 2 $160 - $165M FY24 Product Revenue Guidance © 2024, Iovance Biotherapeutics, Inc. 1. EU & UK 2. Iovance sponsored clinical trials, does not include expanded access or investigator sponsored studies. Abbreviations: BTD=Breakthrough Therapy Designation; FDA=U.S. Food and Drug Administration; RMAT=Regenerative Medicine Advanc ed Therapy Designation Patients Treated in Clinical Studies

4 © 2024, Iovance Biotherapeutics, Inc. Iovance Solid Tumor Portfolio Highlights *Enrollment complete in Cohort 3B; Cohorts 1A and 3D are new planned cohorts Abbreviations: 1L=first line; 2L=second line; 4L=fourth line; FTD=Fast Track Designation; ICI=immune checkpoint inhibitor; IL - 2= interleukin 2; IL - 12=interleukin 12; IND=investigational new drug application; NSCLC=non - small cell lung cancer; PD - 1=programmed cell death protein - 1; TIL=tumor infiltrating lymphocytes Label Expansion Opportunities APPROVED PHASE 3 PHASE 2 PHASE 1 INDICATION & TREATMENT SETTING Post - anti - PD - 1 advanced melanoma (U.S.) EMA & UK submitted; Canada submission planned 2H24 Commercial Amtagvi treatment regimen (U.S.) Advanced melanoma, renal cell carcinoma (U.S., ex - U.S.) TILVANCE - 301 Phase 3 (FTD, Confirmatory) Frontline advanced melanoma Lifileucel + pembrolizumab Registration - Directed IOV - LUN - 202: Cohorts 1&2 Post - chemo & anti - PD - 1 advanced NSCLC Lifileucel IOV - END - 201: Cohorts 1&2 Post - chemo & anti - PD - 1 endometrial cancer Lifileucel Lifileucel Pipeline IOV - COM - 202: Cohorts 3A - 3D* 1 - 4L ICI - naïve & post - anti - PD1 advanced NSCLC Lifileucel, Lifileucel + ICI IOV - COM - 202: Cohorts 1A, 1D* ICI - naïve advanced melanoma Lifileucel + ICI IOV - LUN - 202: Cohort 3 2L post - chemo & post - anti - PD - 1 advanced NSCLC Lifileucel core biopsy IOV - GM1 - 201: Cohort 1 Post anti - PD1 advanced melanoma PD - 1 Inactivated TIL (IOV - 4001) Next - Generation Products IOV - GM1 - 201: Cohort 2 2 - 4L incl. post - anti - PD - 1 advanced NSCLC PD - 1 Inactivated TIL (IOV - 4001) IOV - IL2 - 101 TIL treatment regimen IL - 2 analog (IOV - 3001) Planned Basket trial (planned pre - IND in 2025) IL - 12 tethered TIL (IOV - 5001)

5 © 2024, Iovance Biotherapeutics, Inc. Tumor Infiltrating Lymphocytes (TIL): Leading Cell Therapy Platform for Solid Tumors TIL – Unique Proposed Mechanism of Action • Individualized • One - time therapy • Deploys the patient’s own T cells to fight cancer Tumor Tissue Collection Patient - specific T Cells Grown into the Billions 1 TIL Treatment Regimen 1. Amtagvi USPI

6 © 2024, Iovance Biotherapeutics, Inc. 1. National Cancer Institute Surveillance, Epidemiology and End Results (SEER) Program. 2024 Estimates. https://seer.cancer.g ov (accessed May 2024) 2. World Health Organization International Agency for Research on Cancer (IARC). GLOBOCAN 2022 Global Deaths 2 U.S. Deaths 1 59,000 8,000 Melanoma 1,800,000 125,000 Lung & Bronchus 97,000 13,000 Endometrial 91% of all cancer cases are solid tumors 1 1 .8 M New cases of solid tumors in the U.S. 1 Expand into other indications Significant Market Potential in Solid Tumors and our Key Programs

7 © 2024, Iovance Biotherapeutics, Inc. 1. National Cancer Institute Surveillance, Epidemiology and End Results (SEER) Program. 2024 Estimates. https://seer.cancer.gov (accessed May 2024) 2. World Health Organization International Agency for Research on Cancer (IARC). GLOBOCAN 2022 3. Data on file as of September 30, 2004. Includes more than 20,000 patients initial target markets plus additional potential markets. 4. Validated August 2024 ~30,000 Advanced Melanoma Overall Patient Opportunity 3 Significant Opportunity to Expand Advanced Melanoma Market >70,000 Annual US & Ex - US Addressable Patient Opportunity in Previously Treated Advanced Melanoma 3 Frontline Addressable Patients 3 Annual Deaths 1,2 14K 8K U.S. 27K 22K Ex - U.S. Anticipated Markets 41K 30K Total Geographic Footprint Earlier Treatment Settings UK: 2H 2024 Canada: 2H 2024 EU : 2 Q 2024 4 Australia: 1H 2025 2H 1H 2H 1H Initial Ex - U.S. Regulatory Submissions: Switzerland: 2025 Submitted Planned

10 © 2024, Iovance Biotherapeutics, Inc. Amtagvi Delivered Deep and Durable Responses (95% CI: 21.1, 43.4) mDOR Not Reached ORR 31.4 % (95% CI: 24.1, 39.4) (Range: 1.4+, 45.0+) (Range: 1.4+, 26.3+; 95% CI: 4.1, NR) 18.6 months follow up 21.5 months follow up 2 1. C - 144 - 01 Clinical Trial, Amtagvi USPI 2. Data on file. Abbreviations: CI=confidence interval; mDOR = median duration of response; NR = not reached; ORR=objective response rate Cohort 4 Pivotal 1 (n=73) Supportive Pooled Data 1 (n=153) mDOR Not Reached ORR 31. 5 %

11 © 2024, Iovance Biotherapeutics, Inc. Amtagvi Durability at 4 - Years Follow Up (Pooled Analysis, n=153) 31.4% (95% CI: 24.1, 39.4) ORR Not Reached (95% CI: 8.3, NR) mDOR 48.1 months follow - up 1. Medina et al, ESMO IO 2023 Abbreviations: CI=confidence interval; mDOR = median duration of response; NR = not reached; ORR=objective response rate 21.9% of patients were alive at 4 - year follow - up

*Earlier time to treatment driven by faster reimbursement and scheduling, earlier lymphodepletion, and shorter turnaround for manufacturing/release as the launch continues 12 © 2024, Iovance Biotherapeutics, Inc. Amtagvi Patient Journey Lymphodepletion Reimbursement Approval ~3 Weeks Manufacturing, Release & Shipment Turnaround times will be reduced* Short - Course Scheduling Tumor Procurement Goal: <2 weeks Primary Oncologist ATC Medical Oncologist Patient Post - Regimen Follow - Up & Return to Primary Oncologist TREATMENT ~34 DAYS Community Practice

13 © 2024, Iovance Biotherapeutics, Inc. Iovance Cell Therapy Center: i CTC • Built - to - suit custom facility in Navy Yard Philadelphia • Commercial and clinical TIL therapy supply • Expanding headcount in alignment with expected growth in demand • Control to optimize capacity, quality & COGS FDA - Approved Cell Therapy Manufacturing Facility Dedicated to Commercial and Clinical TIL Cell Therapies COGS= cost of goods sold

14 © 2024, Iovance Biotherapeutics, Inc. Iovance Cell Therapy Center (iCTC): Capacity Expansion Plans i CTC Campus Expansion 10,000+ patients/year i CTC building expansion 3 Automation Today (As built) up to 2,000 + patients/year 1 12 core suites for commercial 4 separate flex suites for clinical Site Expansion (In progress) 2 5,000+ patients/year 24 core suites for commercial 4 separate flex suites for clinical 1. Ongoing staffing, contract manufacturer provides flexibility for incremental additional capacity 2. Expansion within e xis ting shell 3. Option to build on adjacent parcel Pre - Approval (Complete) 100s of patients/year Launch Prep in core suites for commercial 4 separate flex suites for clinical

15 © 2024, Iovance Biotherapeutics, Inc. 15 Amtagvi Authorized Treatment Centers (ATCs) 1 1. Amtagvi.com Note: Not all authorized treatment centers may be listed on the locator tool (Last accessed November 2024) . Abbreviations: ATC=Authorized Treatment Centers Goal to ensure patients have geographic accessibility to ATCs 56 ATCs in November 2024 ~70 ATCs by Year End >90% of Addressable Patients within 200 miles of an ATC

16 © 2024, Iovance Biotherapeutics, Inc. Broad Market Access Data on file as of October 31, 2024. *Plans or policies that cover Amtagvi, including pharmacy benefit managers (PBMs) Abbreviations: NCCN = National Comprehensive Cancer Network Payer medical coverage policies consistent with Amtagvi label, clinical trials and NCCN guidelines Patient lives covered; Majority of patients have private coverage* Typical time to financial clearance 250+ Million ~ 3 Weeks > 75% of Amtagvi patients covered by private payers

18 © 2024, Iovance Biotherapeutics, Inc. Unprecedented Rate, Depth & Durability of Responses in Frontline Advanced Melanoma • Median PFS and median DOR not reached at nearly 2 years of median follow - up (median follow - up 21.7 months) • All response - evaluable patients demonstrated regression of target lesions • Safety consistent with underlying disease and known safety profiles of pembrolizumab, NMA - LD, lifileucel, and IL - 2 • Late AEs consistent with anti - PD - 1 monotherapy, differentiated from ICI combination therapies LIFILEUCEL + PEMBROLIZUMAB IN FRONTLINE ADVANCED MELANOMA: IOV - COM - 202 COHORT 1A 1. Thomas et al, ASCO 2024; Data on file as of May 31, 2024. * Unconfirmed CRs, confirmed following data cut. A One patient without a postdose tumor response assessment was not included. b Target lesion lymph node at baseline decreased by 50% is no longer pathological, and thus is shown here as - 100% representing uCR. CI, confidence interval; CR, complete response; DOR, duration of response; ICI, immune checkpoint inhibitor; ORR, objective response rate; PD, progressive disease; PFS, progression free survival; PR, part ial response; RECIST, Response Evaluation Criteria in Solid Tumors; SD, stable disease; SOD, sum of diameters; AE, adverse event; IL - 2, interleukin - 2; NMA - LD, nonmyeloablative lymphodepletion Data support rationale for TILVANCE frontline study: 1 65.2% ORR via RECIST v 1.1 30.4% CR 64.7% PFS at 6 & 12 months Best Percentage Change from Baseline in Target Lesion SOD Time to Response and Time of Efficacy Assessment for Confirmed Responders (PR or Better)

19 © 2024, Iovance Biotherapeutics, Inc. Option to crossover to lifileucel after BIRC - confirmed PD 1:1 Randomization TILVANCE - 301 Global Phase 3 and Confirmatory Trial LIFILEUCEL + PEMBROLIZUMAB IN FRONTLINE ADVANCED MELANOMA *Pembrolizumab in both arms is started at the same time after randomization. Abbreviations: BIRC=blinded independent review committee; ORR=objective response rate; PD=progressive disease; PD - 1=programmed cell death protein - 1; PFS=progression free survival Arm A: lifileucel plus pembrolizumab* Long - term follow up Patient Population Unresectable or metastatic melanoma; no prior therapy for metastatic disease N=670 48 active sites in U.S., Europe, Australia, Canada >5 0 additional sites committed Arm B: pembrolizumab alone* Study Design with FDA Agreement • Dual primary endpoints: ORR & PFS • Interim analysis on ORR • Final analysis on PFS • Registrational for frontline melanoma • Confirmatory for full approval of Amtagvi in post - anti - PD - 1 melanoma • Enrollment on track with internal projections Randomized, multicenter study with optional crossover to Iifileucel (NCT05727904)

21 © 2024, Iovance Biotherapeutics, Inc. Cohorts investigating multiple treatment regimens and patient populations in 3 Iovance clinical trials Large Domestic and Global Addressable Market in Non - Small Cell Lung Cancer (NSCLC) 1. Clarivate DRG Disease Landscape (2021), figures approximate 2. Data on file as of September 30, 2024, figures approximate 3. American Cancer Society, Lung Cancer. https://www.cancer.org/cancer/types/lung - cancer/about.html accessed July 2023 4. National Cancer Database, NSCLC survival from >1 million patients assessed. Lou Y et al. Survival trends among non - small - cell lu ng cancer patients over a decade: impact of initial therapy at academic centers. Cancer Med. 2018. 2L+ NSCLC Addressable Patient Population 1,2 Frontline NSCLC addressable patient population in U.S. & globally 1,2 210K+ US: 50K Target EU Markets: 50K Globally (2L+): 100K of U.S. cancer deaths, accounting for approx. cancer - related deaths 3 1 in 5 Leading cause Real - world overall survival (US) 4 < 6 mo. 9% 5 - yr survival rate 3

22 © 2024, Iovance Biotherapeutics, Inc. IOV - LUN - 202 Registrational Trial Design Phase 2 Multicenter Study of Lifileucel † in Patients Post - Anti - PD - 1 NSCLC (NCT04614103) † Gen 2 TIL product † † Cohort 3 patients unable to undergo surgical harvest, TIL grown from core biopsy Abbreviations: Anti - PD - 1 = anti - programmed cell death inhibitor; IRC=independent review committee; NSCLC=non - small cell lung cancer; ORR = objective response rate; TPS=tumor proportion score Iovance TIL Therapy Lifileucel in NSCLC IOV - LUN - 202 is designed to enroll patients with advanced NSCLC with a high unmet medical need, post anti - PD - 1 treatment Endpoints • Primary: ORR by IRC • Secondary: Safety Patient Population Unresectable or metastatic NSCLC with progression on or after prior anti - PD - 1 treatment and chemotherapy ~35 sites and expanding in U.S., Canada, Europe, APAC Cohort 1: < 1% or unknown TPS Cohort 2: ≥ 1% TPS Cohort 3: Core Biopsy and Gen3 †† Cohort 4 : P re - progression tumor harvest Retreatment Cohort Exploratory Cohorts Registrational Cohorts Data for registrational cohorts anticipated in 2025

23 © 2024, Iovance Biotherapeutics, Inc. Strong Preliminary Clinical Results in Second - Line mNSCLC IOV - LUN - 202 COHORTS 1 AND 2, POST - ANTI - PD - 1 NSCLC % Change from Baseline (n=23) Patients *Data cut: July 6, 2023. 21 evaluable patients for response. Responses were assessed by investigator; **Updated analysis in November 2023 showed additional ongoing responses (not indicated in above charts) 1 . Patients who have progressed on or after chemotherapy and anti - PD - 1 therapy for advanced (unresectable or metastatic) NSCLC wi thout EGFR, ROS or ALK genomic mutations and had received at least one line of an FDA - approved targeted therapy if indicated by other actionable tumor mutations. 2. A bar is presented for each patient starting from date of Lifileucel infusion up to date of new anti - cancer therapy, end of asse ssment, death, or data cutoff date, whichever occurs earlier. Abbreviations: AE, adverse event; CI, confidence interval; CR, complete response; DOR, duration of response; ICI, immune checkpoint inhibitor; NE, not evaluable; NMA - LD, non - myeloablative lymphodepletion; NSCLC, non - small cell lung cancer; ORR, objective response rate; PD, progressive disease; PR, partial response; SD, stable disea se; SOD, sum of diameters; TEAE, treatment - emergent AE ; TPS, tumor proportion score. Tumor Reduction and Deep, Durable Responses in Previously Treated NSCLC, Regardless of PD - L1 Status 1 Best Percentage Change from Baseline in Target Lesion SOD 26.1% ORR by RECIST 1.1, Regardless of PD - L1 Status* 2 Duration of response >6 months for 71% of confirmed responders in the trial**

24 © 2024, Iovance Biotherapeutics, Inc. Cohort 3A Results Support Adding TIL Therapy to Frontline NSCLC 1 IOV - COM - 202 COHORT 3A, ICI - NAÏVE NSCLC % Change from Baseline Time (Months) Since TIL Infusion Patients PD - L1 negative, EGFR WT subgroup has a high unmet need 2 Best Percentage Change from Baseline in Target Lesion SOD 64.3% ORR EGFR WT Time to Response for Confirmed Responders (PR or Better, EGFR WT Patients) mDOR not reached (median follow - up 26.5 months) • Safety consistent with Iovance TIL combination studies • Supports adding TIL therapy to pembrolizumab plus chemotherapy for frontline NSCLC in new IOV - COM - 202 cohort 1. Creelan et al,SITC 2024 2 . KEYTRUDA USPI; OPDIVO USPI *PR response based on target lesion reduction of 100% with the persistence of nontarget lesions. Abbreviations: CR, complete response; EGFR, epidermal growth factor receptor; ICI, immune checkpoint inhibitor; NSCLC, non - small - cell lung cancer; ORR, objective response rate; PD, progressive disease; PR, partial response; RECIST, Response Evaluation Criteria in Solid Tumors; SD, stable disease; SOD, sum of diameter; TPS, tumor proportion score; WT, wild - type 54.5% ORR EGFR WT PD - L1 Negative by RECIST 1.1 Anti - PD - 1 ORR Benchmarks 2 27% (TPS ≥ 1%); 39 - 45% (TPS ≥ 50%) Treatment - naïve (mono) 18 - 20% Post - chemotherapy (mono) 48 - 58% Frontline (anti - PD - 1 + chemo) 2 60 40 20 0 – 20 – 40 – 60 – 80 – 100 a 3A - 03 3A - 16 3A - 08 3A - 22 3A - 15 3A - 09 3A - 04 3A - 02 3A - PD - L1 TPS <1 <1 <1 <1 ≥ 50 <1 <1 <1 <1 3A - 10 ≥ 50 3A - 17 ≥ 50 3A - 11 <1 3A - 13 <1 8 0 10 0 PD SD PR CR

25 © 2024, Iovance Biotherapeutics, Inc. 1. National Cancer Institute Surveillance, Epidemiology and End Results (SEER) Program. 2024 Estimates. https://seer.cancer.gov (ac cessed May 2024); 2. World Health Organization International Agency for Research on Cancer (IARC). GLOBOCAN 2022 3. NCCN Guidelines Version 2.2024 Endometrial Carcinoma; 4. Kang et al, Nature Portfolio, Scientific Reports, 2022; 5. Makker V, et al. N Engl J Med. 2022; 6. McMeekin S, et al. Gynecol Oncol. 2015. Abbreviations: Anti - PD - 1 = anti - programmed cell death inhibitor; pMMR = proficient DNA mismatch repair; dMMR = deficient DNA mismatch repair; SOC=standard of care; TMB - H = tumor mutational burden high; ORR = objective response rate Potential Market for Advanced Endometrial Cancer LIFILEUCEL IN ADVANCED ENDOMETRIAL CANCER Immunosensitive Tumor Type with Significant Unmet Need in 2L+ Anti - PD - (L)1 moving into front - line therapy setting 3 No standard of care for 2L+ post - anti - PD - 1 • Molecularly defined subgroups with available targeted therapies are small • ORR with mono - chemotherapy after front - line chemo doublet: ~15% 5,6 • Limited data on treatments after anti - PD - (L)1 13,300 97,000 US annual uterine cancer deaths 1 5 - yr survival (distant metastases) 1 Global deaths 2 18.9% Endometrial Cancer Biomarkers 4 dMMR: 27% pMMR: 73% 90%+ of Uterine Cancers are Endometrial

26 © 2024, Iovance Biotherapeutics, Inc. pMMR Subgroup dMMR Subgroup Endpoints • Primary : ORR per RECIST v1.1 by investigator • Secondary : CR rate , DOR, DCR, PFS, OS, safety and tolerability • Subgroup analyses specified in protocol • Potential to expand / convert to registrational trial • First patient enrolled Q4 2024 IOV - END - 201 Phase 2 Proof of Concept Study Endometrial Cancer Patient Population * Recurrent, metastatic or primary unresectable disease after chemo and anti - PD - 1 therapy ≤ 3 lines of prior systemic therapy with no more than 1 line of chemotherapy *Sample size and study population of registrational ph2 study will be determined after PoC final analysis Abbreviations: Anti - PD - 1, anti - programmed cell death inhibitor; CR, complete response; dMMR, mismatch repair deficient; pMMR, mi smatch repair proficient; DCR, disease control rate; DOR, duration of response; ORR, objective response rate; OS, overall survival; PFS, progression free survival LIFILEUCEL IN ADVANCED ENDOMETRIAL CANCER Proof - of - Concept Trial in Patients with Mismatch Repair (MMR) Proficient and Deficient Tumors (NCT06481592)

27 © 2024, Iovance Biotherapeutics, Inc. 27 © 2024, Iovance Biotherapeutics, Inc. IOV - 4001: PD - 1 Inactivated TIL Therapy 2 T cell PD - 1 PD - 1 inhibits the ability of T cells to fight cancer: T cells, upon encountering cancer cells, produce PD - 1, a checkpoint receptor that is activated by proteins (PD - L1 and PD - L2) found on cancer and other immune cells. 1 PD - L2 PD - L1 PD - 1 TCR pMHCI PD - L2 PD - L1 Tumor cell Antigen - presenting cell 1. Sharpe AH, Pauken KE, Nat Rev Immunol 2018, 18:153 - 167 2. Natarajan A, Cubas R et.al. AACR 2022 3. Licensed from Cellectis 1 IOV - 4001 TCR pMHCI PD - L2 PD - L1 Tumor cell PD - 1 Inactivated T Cells Avoid Checkpoint Signals: PD - 1 is inactivated using TALEN, restoring the ability of TIL cells to kill cancer cells. 2,3 Cognate Antigen Cognate Antigen

28 © 2024, Iovance Biotherapeutics, Inc. Phase 1/2 Open - Label First - in - Human Study: IOV - GM1 - 201 Endpoints • Phase 1: Safety (Complete) • Phase 2 Primary: ORR per RECIST v1.1 by investigator • Secondary : CR rate , DOR, DCR, PFS, OS, safety and tolerability Genetically Modified, PD - 1 Inactivated TIL Therapy IOV - 4001 in Previously Treated Metastatic Melanoma and NSCLC (NCT05361174) Cohort 1: Unresectable or metastatic melanoma Post - anti - PD - 1/L1, post - BRAF/MEK inhibitor in patients with BRAF mutations Cohort 2: Stage III or IV NSCLC Post - anti - PD - 1/L1 or post targeted therapy and either chemotherapy or anti - PD - 1/L1 Patient Population Adults with unresectable or metastatic melanoma or advanced NSCLC N=53 NEXT - GENERATION TIL THERAPY: IOV - 4001 Abbreviations: Anti - PD - 1 = anti - programmed cell death inhibitor; CR=complete response;; DCR=disease control rate; DOR=duration of response; NSCLC=non - small cell lung cancer; ORR=objective response rate; OS=overall survival; PFS= progression free survival

29 © 2024, Iovance Biotherapeutics, Inc. 29 © 2024, Iovance Biotherapeutics, Inc. IOV - 3001: Next Generation IL - 2 for TIL Supportive Regimen Recombinant fusion protein designed to enhance TIL survival and cellular proliferation • A modified copy of the coding sequence for aldesleukin (mdIL - 2) is fused to a humanized monoclonal immunoglobulin (Ig)G1 κ antibody • The mdIL - 2 moiety of IOV - 3001 binds to the IL - 2 - receptor (IL - 2R) with subsequent phosphorylation of signal transducer and activator of transcription 5 (STAT5), resulting in enhanced performance Mitra S, Leonard WJ, Journal of Leukocyte Biology 2018 103(4 ): 643 - 655 Simpson - Abelson et al, ASCO 2024 Simpson - Abelson MR, Johnson S et al, ASCO 2024. Gene Expression: • Survival • Proliferation mdIL - 2 IL - 2R JAK1 P JAK3 STAT5 dimer Cytosol Nucleus P IOV - 3001 IOV - 3001 Heavy chain Light chain IOV - 3001 Modified IL - 2 (mdIL - 2) TIL Antibody Preclinical data suggest IOV - 3001 may have a better safety profile and require less frequent dosing compared to Proleukin

30 © 2024, Iovance Biotherapeutics, Inc. IOV - 5001: IL - 12 TIL Therapy to Increase Efficacy 1. Zhang L, Rosenberg SA, et al, Clin Cancer Res 2015;21(10):2278 – 2288 2. Zhang L, Davis JS, et al, J Immunother Cancer 2020;8:e000210 3. Kobayashi M, Fitz L, et al, J Exp Med 1989;170:827 – 845. 4. Zeh HJ, Hurd S et al, J Immunother 1993;14:155 – 61. 5. Tugues S, Burkhard SH, et al, Cell Death and Differentiation 2015;22:237 – 246. 6. Cao X, Leonard K, et al, Cancer Res 2009;69:8700 – 9. 7. Steding CE, Wu S, et al, Immunology 2011;133:221 – 38. • Tethered IL - 12 TIL cells can improve efficacy by remodeling the suppressive TME into an immuno - supportive state – In advanced melanoma patients, an ORR of 63% (n=16) was observed with prior generation IL - 12 secreting TIL product at doses 10 - to 100 - fold lower than conventional TIL products 1 • IL - 12 shows independent clinical efficacy, with safe delivery to the TME being the primary challenge 1,2 • Expression of IL - 12 on IOV - 5001 is induced upon antigen encounter in the TME 1,2 • IOV - 5001’s expressed IL - 12 is tethered to the membrane surface of TIL to avoid release into circulation (shedding) 2 • Inducible IL - 12 expression in the TME and lack of IL - 12 shedding are expected to allow increased IOV - 5001 cell doses and improved TIL efficacy in solid tumor cancers IL=12 = interleukin 12; MDSC = myeloid derived suppressor cell; NK = natural killer cell; NKT = natural killer T cell; ORR = obj ective response rate; TME = tumor microenvironment; Treg = regulatory T cell NK and NK - T cell activation and proliferation 3 CD8 + T cell activation and proliferation 4 CD4 + T cell differentiation to Th1 5 T reg and MDSC downregulation 6,7 30 Direct Action IFN γ Cytosol Nucleus TIL NFAT - TeIL - 12 IL - 12 IL - 12R TCR Antigen © 2024, Iovance Biotherapeutics, Inc.

32 © 2024, Iovance Biotherapeutics, Inc. (in millions) September 30, 2024 $403.8 1 Cash position 304.6 Common shares outstanding 2.9 2 Preferred shares outstanding 28.8 Stock options and restricted stock units outstanding 1. Includes net proceeds of approximately $200.0 million raised from an at - the market (ATM) equity financing facility during the se cond and third quarter of 2024 2. Preferred shares are shown on an as - converted basis 3. Includes anticipated revenue from Amtagvi and Proleukin® 4. Q3 total product revenue of $58.6 million and cost of sales $39.8 million, primarily attributed to $8.3 million in period cos ts associated with patient drop off and manufacturing success rates, $5.5 million for non - cash amortization expense for intangible assets, and $3.9 million in royalties payable on product sales Strong Financial Position for Launch Success and Pipeline Growth Cash runway is sufficient into early 2026 3 Gross margins expected to increase to >70% over next several years 4

33 © 2024, Iovance Biotherapeutics, Inc. □ Obtain FDA approval for lifileucel in advanced melanoma (approved on Feb. 16, 2024) □ Submit EMA regulatory dossier (1H24) (Validated by EMA) □ Submit additional ex - U.S. dossiers (2H24) (UK complete, Canada underway) □ Present data for NSCLC frontline and pursue registrational pathway REGULATORY □ Report clinical and pre - clinical data □ Resume enrollment in IOV - LUN - 202 □ Initiate Phase 2 trial in endometrial cancer □ Continue to enroll patients in clinical trials for advanced melanoma, NSCLC and gynecological cancers □ Advance new products toward clinic, including additional genetically - modified TIL therapies PIPELINE □ Fulfill patient demand for commercial launch and clinical trials □ Further expand capacity to meet U.S. and ex - U.S. demand MANUFACTURING □ Execute commercial launch (1Q24) □ On - board 50 ATCs within 90 days of PDUFA date □ On - board ~70 ATCs by end of 2024 COMMERCIAL Abbreviations: ATC=Authorized Treatment Centers; EMA=European Medicines Agency; FDA=U.S. Food and Drug Association; NSCLC=non - sm all cell lung cancer; PDUFA=Prescription Drug User Fee Act Anticipated 2024 Milestones

34 © 2024, Iovance Biotherapeutics, Inc. Corporate Highlights Pioneering a Transformational Approach to Cure Cancer 34 © 2024, Iovance Biotherapeutics, Inc. Abbreviations: FTD, fast track designation; ICI, immune checkpoint inhibitor; NSCLC, non - small cell lung cancer; PD - 1, programme d cell death protein - 1 Fully - Integrated for Commercial Success Efficient and Scalable Proprietary Manufacturing Facility First FDA Approved T Cell Therapy for a Solid Tumor Cancer Large Market Opportunity in High Unmet Need Cancers • Experienced cross - functional cell therapy team • TIL service - line capabilities established with leading U.S. cancer centers • IovanceCares proprietary platform • Iovance Cell Therapy Center ( i CTC) in - house manufacturing • Ample capacity for U.S. launch and global clinical trials • Additional capacity with contract manufacturer • FDA accelerated approval for Amtagvi in advanced melanoma • TILVANCE - 301 Phase 3 confirmatory trial in frontline advanced melanoma (FTD) • Defined registration strategy in NSCLC • Regulatory dossiers under review, submitted or planned across multiple international markets • Initial focus in post - ICI solid tumors • Expansion into combinations, new tumor types, earlier lines of therapy and genetic modifications • Key late - stage trials in melanoma, NSCLC • First - in - human trial of genetically modified PD - 1 inactivated TIL

Iovance Biotherapeutics (IOVA) 8-KOther Events